Neostigmine | |
---|---|
Salts [] | |
---|---|
Neostigmine mesylate | |
Molecular structure via molpic | |
Conformer structure via 3Dmol.js | |
Molecular formula | C12H19N2O2+[1] |
---|---|
Molecular mass | 223.29 g/mol[1] |
Predicted LogP | 1.5[1] |
Solubility | 6.77e-02 g/L[1] |
Chirality | achiral[2] |
Identifiers [] | |
---|---|
IUPAC name | [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium[1] |
SMILES | CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C[1] |
InChI | InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1[1] |
InChIKey | ALWKGYPQUAPLQC-UHFFFAOYSA-N[1] |
Dosing | |
---|---|
Elimination half-life | 50–90 minutes |
Duration of action | up to 4 hrs |
Neostigmine
Neostigmine (also known as Eustigmin, Eustigmine, Vagostigmine, Prostigmin, Juvastigmin, Neostigmin, Neostigminum, Intrastigmina, m-Trimethylammoniumphenyldimethylcarbamate or 3-Trimethylammoniumphenyl N,N-dimethylcarbamate)
Chemistry
Neostigmine is typically found in the form of its mesylate salt.
Stereochemistry
Neostigmine is a achiral mixture
Legal status
- Australia: Neostigmine is a S4 substance.
- United Kingdom: Neostigmine is a prescription only substance.
- United States: Neostigmine is a prescription only substance.